Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study.
- 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- 2Susan & Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- 3Department of Pediatrics, Division of Pediatric Gastroenterology & Nutrition, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Abstract
Background
Early case reports and observational studies have suggested an association between isotretinoin and inflammatory bowel disease (IBD). However, large cohort studies and meta-analyses have not demonstrated a meaningful association between isotretinoin use and IBD development. Most prior research has focused on incident IBD risk, with limited attention to disease activity among patients with established IBD.Methods
We conducted a single-center retrospective cohort study of patients with Crohn's disease (CD) or ulcerative colitis (UC) treated with isotretinoin between 2015 and 2025. Inclusion required at least 1 IBD assessment within the 4 months before and 12 months after isotretinoin initiation. Disease activity was assessed using Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), inflammatory biomarkers, and in some patients, intestinal ultrasound and fecal calprotectin. The primary outcome was composite IBD status change, defined as new clinical activity (Δ ≥ 1 in HBI/pMS), or isotretinoin discontinuation attributed to IBD activity.Results
Thirty-seven patients met inclusion criteria (57% CD, 43% UC). Most patients were in clinical remission at baseline (86%). Following isotretinoin exposure, 92% remained in remission, with no significant changes in HBI, pMS, erythrocyte sedimentation rate, C-reactive protein, or fecal calprotectin. IBD status change occurred in 4 patients (11%), with events largely attributable to underlying IBD-related factors, including biologic transitions, anti-drug antibody development, or medication dose adjustments.Conclusions
Among patients with established, well-controlled IBD, isotretinoin was not associated with clinically meaningful worsening of disease activity, supporting its use in carefully selected patients with stable disease.
Related
- Cyclosporine Plus Isotretinoin for Darier Disease: A Preliminary Observation in Three Patients.
- Risk factors and prediction model of renal dysfunction in patients with inflammatory bowel disease: a retrospective cohort study.
- Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study
- Individualized Gabor Flicker for Well-Tolerated Neural Entrainment During Working Memory
- Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.
BibTeX
@article{cutrona2026acne,
title = {{Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study.}},
author = {Marley Cutrona and Ahuva Cices and Marla C Dubinsky and Elizabeth A Spencer},
journal = {Crohn's \& colitis 360},
year = {2026},
month = oct,
doi = {10.1093/crocol/otag110},
url = {https://europepmc.org/article/MED/42890950},
note = {CC BY},
}
RIS
TY - JOUR
TI - Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study.
AU - Marley Cutrona
AU - Ahuva Cices
AU - Marla C Dubinsky
AU - Elizabeth A Spencer
PY - 2026
DA - 2026/10/05
JO - Crohn's & colitis 360
DO - 10.1093/crocol/otag110
UR - https://europepmc.org/article/MED/42890950
AB - Background Early case reports and observational studies have suggested an association between isotretinoin and inflammatory bowel disease (IBD). However, large cohort studies and meta-analyses have not demonstrated a meaningful association between isotretinoin use and IBD development. Most prior research has focused on incident IBD risk, with limited attention to disease activity among patients with established IBD.Methods We conducted a single-center retrospective cohort study of patients with Crohn's disease (CD) or ulcerative colitis (UC) treated with isotretinoin between 2015 and 2025. Inclusion required at least 1 IBD assessment within the 4 months before and 12 months after isotretinoin initiation. Disease activity was assessed using Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), inflammatory biomarkers, and in some patients, intestinal ultrasound and fecal calprotectin. The primary outcome was composite IBD status change, defined as new clinical activity (Δ ≥ 1 in HBI/pMS), or isotretinoin discontinuation attributed to IBD activity.Results Thirty-seven patients met inclusion criteria (57% CD, 43% UC). Most patients were in clinical remission at baseline (86%). Following isotretinoin exposure, 92% remained in remission, with no significant changes in HBI, pMS, erythrocyte sedimentation rate, C-reactive protein, or fecal calprotectin. IBD status change occurred in 4 patients (11%), with events largely attributable to underlying IBD-related factors, including biologic transitions, anti-drug antibody development, or medication dose adjustments.Conclusions Among patients with established, well-controlled IBD, isotretinoin was not associated with clinically meaningful worsening of disease activity, supporting its use in carefully selected patients with stable disease.
SN - 2631-827X
ER -